LUND, Sweden, Aug. 20, 2019 /PRNewswire/ -- BioInvent
International AB's (publ) (OMXS: BINV) partner Oxurion NV has today
reported topline data from a Phase lla study evaluating THR-317, a
humanized antibody against placental growth factor (PlGF), in
combination with anti-VEGF (ranibizumab), an anti-vascular
endothelial growth factor (VEGF) antibody, for the treatment of
Diabetic Macular Edema (DME).
- Combination therapy did not show increase in best corrected
visual acuity (BCVA) in the overall population at Month 3.
- Certain improvement in mean BCVA at Month 3 observed with the
combination therapy in 2 pre-specified subgroups:
- poor (or non) responders to prior anti-VEGF
- patients with poor vision - baseline BCVA ≤65 letters.
- Topline data confirm THR-317 in combination with ranibizumab is
safe and well-tolerated.
In 2017, Oxurion NV gained full and exclusive ownership of
THR-317 for development and commercialization in all non-oncology
indications. In exchange, BioInvent is entitled to five percent of
the program's economic value.
For further information, see Oxurion's press release of
August 20, 2019
(www.oxurion.com).
About BioInvent
BioInvent International AB (OMXS: BINV) is focused on the
discovery and development of novel and first-in-class
immuno-modulatory antibodies to treat cancer. The Company's lead
program BI-1206, is currently in Phase l/ll for non-Hodgkin
lymphoma and chronic lymphatic leukemia. BioInvent's pre-clinical
portfolio is focused on targeting key immune suppressive cells and
pathways of the tumor microenvironment, including regulatory T
cells, tumor-associated myeloid cells and mechanisms of antibody
drug-resistance. The Company has a strategic research collaboration
with Pfizer Inc., and partnerships with Transgene, Bayer Pharma,
Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates
near term revenues from its fully integrated manufacturing unit
producing antibodies for third parties for research through to
late-stage clinical trials. More information is available at
www.bioinvent.com.
BioInvent International AB (publ)
For further
information, please contact:
|
|
Martin Welschof,
CEO
|
Hans Herklots,
LifeSci Advisors
|
|
|
+46 (0)46 286 85
50
|
+41 79 598 71
49
|
martin.welschof@bioinvent.com
|
martin.welschof@bioinvent.com
|
|
|
|
|
|
|
|
|
Co. Reg. No. Org nr: 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46-286-85-50
www.bioinvent.com
The press release contains statements about the future, consisting
of subjective assumptions and forecasts for future scenarios.
Predictions for the future only apply as the date they are made and
are, by their very nature, in the same way as research and
development work in the biotech segment, associated with risk and
uncertainty. With this in mind, the actual outcome may deviate
significantly from the scenarios described in this press
release.
This information was brought to you by Cision
http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/583/2884603/1092571.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/bioinvents-partner-oxurion-nv-has-reported-topline-month-3-results-of-phase-lla-study-evaluating-thr-317-anti-plgf-in-combination-with-ranibizumab-for-dme-300904225.html
SOURCE BioInvent